Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction

7/8/24 8:05:52 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AVTE alert in real time by email

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.

Get the next $AVTE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVTE

Date	Price Target	Rating	Analyst
6/18/2024	$27.00 → $2.00	Outperform → In-line	Evercore ISI
6/18/2024		Buy → Hold	TD Cowen
6/18/2024	$35.00 → $2.00	Overweight → Equal Weight	Wells Fargo
6/17/2024		Buy → Neutral	Guggenheim
6/17/2024		Buy → Neutral	BTIG Research
6/17/2024	$41.00 → $3.00	Outperform → Neutral	Wedbush
3/25/2024	$21.00 → $65.00	Buy	Jefferies
12/8/2023	$35.00	Equal Weight	Wells Fargo

More analyst ratings

$AVTE
Press Releases

Fastest customizable press release news feed in the world

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
Merger to create a company focused on advancing Jade Biosciences' portfolio of novel therapies that aim to redefine the standard of care for patients with autoimmune diseases Jade Biosciences, the fourth company founded on assets licensed from Paragon Therapeutics, expects to initiate a clinical trial for JADE-001 in the second half of 2025 Approximately $300 million raised to date, including anticipated proceeds from an oversubscribed pre-closing private financing, expected to fund operations through 2027 Conference call scheduled for October 31, 2024, at 8:30 AM EDT VANCOUVER, British Columbia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AV
10/31/24 7:00:00 AM ET
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care
Aerovate Therapeutics to Explore Strategic Alternatives
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this review process, Aerovate has engaged Wedbush PacGrow as the company's exclusive strategic financial advisor to assist in the process of exploring strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse mer
7/8/24 8:00:00 AM ET
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
WALTHAM, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH). The objective of the Phase 2b portion of IMPAHCT was to assess the efficacy, safety and tolerability of three different doses of AV-101 compared to placebo. The primary endpoint for the Phase 2b portion of IMPAHCT is change in PVR compared with placebo. Results
6/17/24 8:32:00 AM ET
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board. "We are pleased to have Habib take on the role of Chair of the Board," said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics. "With the Phase 2b data readout from our global IMPAHCT trial of AV-101 in PAH coming in June and our Phase 3 trial already well underway,
3/6/24 8:00:00 AM ET
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate's Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies. "We are excited to welcome Habib to Aerovate's Board of Directors. Habib's deep experience in leading both big pharma and emerging biotech companies will be incredibly
7/11/23 5:00:00 PM ET
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate's Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies. "We are excited to welcome Don to Aerovate's Board of Directors. Don's proven track record of leading and building biopharmaceutical companies from the ground up and taking them through extensive periods of g
1/23/23 8:00:00 AM ET
$AVTE
Biotechnology: Pharmaceutical Preparations
Health Care

Aerovate Therapeutics To Explore Strategic Alternatives Which May Include But Are Not Limited To, An Acquisition, Merger, Reverse Merger, Business Combination, Liquidation Or Other Transaction

Chat with this insight

Recent Analyst Ratings for $AVTE

$AVTE Press Releases

Fastest customizable press release news feed in the world

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement